Bio
Mauro Mileni is the Founder and CEO of Abilita Therapeutics. He established the company with the aim of translating concepts forged from years of working on difficult membrane proteins often called “undruggable”, such as GPCRs and ion channels, into groundbreaking new technologies capable of overcoming fundamental obstacles and making them “druggable”. Mauro had long envisioned an innovative approach that would harness the power of evolution to address inherent challenges associated with the membrane proteins themselves, a technology that can improve their properties and enable discovery for virtually any target. Before founding Abilita, Mauro earned a Ph.D. from the Max Planck Institute of Biophysics, Frankfurt am Main, did postdoctoral work at The Scripps Research Institute, and was a key structural biology scientist at Receptos, Inc.
